As many of you know, we’re unfortunately finding Mast Cell Activation Diseases aka “MCAD” of all kinds (forms of masto or the newly recognized MCAS and even newer HaTS since 2016) to be relatively common in Ehlers-Danlos patients, which is why I’ve written about them at length. I’m so grateful to Patricia Murray-Wood for following